CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
0.7120
2.84%
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.0171
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023401 %
Charges from full value of position ($-4.45)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023401%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001179 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001179%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.736
Open 0.7308
1-Year Change 62.47%
Day's Range 0.7069 - 0.7308
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 24, 2024 0.7120 -0.0251 -3.41% 0.7371 0.7378 0.7069
Dec 23, 2024 0.7360 -0.0254 -3.34% 0.7614 0.7635 0.7188
Dec 20, 2024 0.7609 0.0039 0.52% 0.7570 0.7962 0.7269
Dec 19, 2024 0.7613 -0.0057 -0.74% 0.7670 0.7740 0.7439
Dec 18, 2024 0.7513 -0.0656 -8.03% 0.8169 0.8369 0.7369
Dec 17, 2024 0.8250 -0.0120 -1.43% 0.8370 0.8400 0.8109
Dec 16, 2024 0.8394 0.0125 1.51% 0.8269 0.8863 0.8069
Dec 13, 2024 0.8528 -0.0003 -0.04% 0.8531 0.8690 0.8169
Dec 12, 2024 0.8497 -0.0076 -0.89% 0.8573 0.8870 0.8374
Dec 11, 2024 0.8630 -0.0129 -1.47% 0.8759 0.8777 0.8301
Dec 10, 2024 0.8779 -0.0035 -0.40% 0.8814 0.9076 0.8369
Dec 9, 2024 0.8798 -0.0019 -0.22% 0.8817 0.9196 0.8670
Dec 6, 2024 0.8651 -0.0018 -0.21% 0.8669 0.9036 0.8579
Dec 5, 2024 0.8655 -0.0124 -1.41% 0.8779 0.8976 0.8619
Dec 4, 2024 0.8828 -0.0291 -3.19% 0.9119 0.9175 0.8769
Dec 3, 2024 0.9021 -0.0214 -2.32% 0.9235 0.9399 0.8979
Dec 2, 2024 0.9355 -0.0314 -3.25% 0.9669 0.9803 0.9269
Nov 29, 2024 0.9719 0.0050 0.52% 0.9669 1.0069 0.9669
Nov 27, 2024 0.9624 0.0385 4.17% 0.9239 0.9969 0.9193
Nov 26, 2024 0.9030 -0.0239 -2.58% 0.9269 0.9294 0.8969

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

People also watch

Gold

2,625.68 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0147%
Short position overnight fee 0.0065%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,714.60 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

95,502.25 Price
-3.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

3,362.05 Price
-3.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading